Biotest Pharmaceuticals Corporation
Guided by a quest for quality, driven by a search for solutionswith a proven commitment to safety.
Biotest Pharmaceuticals Corporation, headquartered in Boca Raton, Fla., was formed in 2007 as part of the Biotest AG acquisition of the Nabi Biopharmaceuticals Biologics business unit. Biotest Pharmaceuticals researches and manufactures biotherapeutic products specializing in immunology and liver transplant therapy. A leader in the collection of human plasma, Biotest Pharmaceuticals Corporation is currently involved in the development of products for Primary Immune Deficiency (PID) and for liver transplantation. With its high standards for excellence, focus on safety and state-of-the-art facilities, Biotest Pharmaceuticals is an ideal fit with its parent company, Biotest AG.
At a Glance
5800 Park of Commerce Blvd., N.W.
Boca Raton, FL 33487
Web site: www.biotestpharma.com
Biotest is focused on research and development of biotherapeutic products for Primary Immune Deficiency (PID) and liver transplantation. A leader in the collection of human plasma, Biotest products include Nabi-HB® for post-exposure prophylaxis of hepatitis B.
Biotest AG, headquartered in Dreieich, Germany, is a highly respected world leader in the development and manufacture of pharmaceutical and biotherapeutic products for immunology and hematology. With Biotest Pharmaceuticals, Biotest AG shares an exacting and corporate-wide focus on product safety and quality, state-of-the-art facilities and advanced manufacturing technology. This focus on consistency and quality ensures that patients and providers experience dependable outcomes across all product lines.
Biotest Pharmaceuticals Corporation:
Leading the Way in HBV Post-Exposure Prophylaxis
Biotest Pharmaceuticals Corporation has several new product candidates in its pipeline and one FDA-approved productNabi-HB®. In the United States, Nabi-HB is currently the leading immunoglobulin product prescribed for post-exposure prophylaxis of hepatitis B. Nabi-HB has a well-documented record of long-term safety and unsurpassed effectiveness. The combined offering of Nabi-HB (sold in the United States by Biotest Pharmaceuticals Corporation) and Hepatect® (sold abroad by Biotest AG) makes Biotest AG the largest provider of hepatitis B hyperimmune globulin in the world.
The companys pipeline of important, new plasma-based products includes IGIV, a polyvalent immunoglobulin (Phase III), anti-Dfor prevention of Rh isoimmunization in Rh-negative patientsand Civacir®, for the prevention of hepatitis C in liver transplant patients.
Biotest Pharmaceuticals Corporation, a world leader in human plasma collection for therapeutic product production, operates 10 state-of-the-art plasmapheresis centers located throughout the United States that are licensed by both the FDA and the European Medicines Agency (EMEA). Biotest AG operates eight centers in Europe that are EMEA-licensed. These centers enable the company to ensure the highest-quality raw material for both its own development and manufacturing, and for third-party use. Biotest Pharmaceuticals state-of-the-art plasma protein production plant in Boca Raton, Fla., is compliant with cGMP (Current Good Manufacturing Practices) and FDA-licensed. Built in 2002, the current facility includes labs, enhanced quality controls and ample storage capacity. Immediate plans for expansion include increasing the current fractionation capacity up to 400,000 L and enhancing Biotest Pharmaceuticals Corporations already significant capabilities.
The formation of Biotest Pharmaceuticals Corporation in the United States allows Biotest AG to participate in the growing U.S. immunoglobulin market, which is estimated to comprise approximately 34 million grams in 2007. According to Rainer Pabst, PhD, chief executive officer of Biotest Pharmaceuticals Corporation, We are looking forward to building upon this foundation to reach our goals of continued growth and ongoing development of high-quality plasma products.
The parent corporation, Biotest AG, was founded in 1946. Headquartered just outside of Frankfurt, Germany, it employs more than 1,800 people worldwide (including more than 500 U.S.-based Biotest Pharmaceutical employees). Its product lines encompass plasma proteins, biotherapeutics and diagnostics.
In biotherapeutics, Biotest AG currently has three clinical-stage drug product candidates under development: BT-061 (for rheumatoid arthritis and psoriasis), BT-062 (multiple myeloma) and BT-063 (systemic lupus erythematosus). Each displays unique properties that differentiate them from other currently marketed therapeutics. Its diagnostics products include reagents, serology and microbiology systems.
Product sales for Biotest AG totaled over 325 million euro in 2007. Its products are sold to health care facilities in over 90 countries, with over 68% of sales generated outside of Germany.
Biotest Pharmaceuticals Corporation will continue its commitment of working closely with clinicians, health care providers and pharmacy partners, to build strong relationships that advance the cause of safe and effective patient care.
For more information on the company and its products, visit the Biotest Pharmaceuticals Corporation Web site at www.biotestpharma.com.